Blutzuckerwerte bei chronisch schizophrenen Patienten unter antipsychotischer Behandlung

Zusammenfassung

Anliegen Untersuchung der Blutzuckerwerte chronisch schizophrener Patienten unter antipsychotischer Behandlung. Methode Auswertung der Nüchternblutzuckerwerte von 177 Patienten nach einer Behandlungsdauer von 17,8 ± 8,7 Jahren. Ergebnisse 24,3 % hatten erhöhte Nüchternblutzuckerwerte (≥ 126 mg/dl). Dieser Anteil ist höher als der von Diabetikern in der Allgemeinbevölkerung. Die verschiedenen Gruppen von Antipsychotika wiesen Unterschiede hinsichtlich der Häufigkeit erhöhter Blutzuckerwerte auf. Schlussfolgerungen Langfristig mit Antipsychotika behandelte schizophrene Patienten haben ein erhöhtes Risiko pathologischer Blutzuckerwerte.

Abstract

Objective There is some evidence that the treatment with new („atypical”) antipsychotics is associated with a higher frequency of type 2-diabetes mellitus. Aim In this study the blood glucose levels of consecutively admitted inpatients with chronic schizophrenia were investigated. Methods The base blood glucose levels of 177 consecutively admitted chronic schizophrenic patients were evaluated. Results After long-term treatment (mean duration: 17.8 ± 8.7 years [range 5 - 44 years]) 24.3 % of the investigated patients showed elevated base blood glucose levels (≥ 126 mg/dl). The proportion of patients with elevated blood glucose levels among the schizophrenic patients treated with antipsychotics was significantly higher than the proportion of diabetics in the corresponding age groups in the general population. The comparison of different groups of antipsychotics revealed that those patients treated with conventional neuroleptics and non-dibenzodiazepine derviates (i. e. risperidone) had a lower risk of developing diabetes mellitus than those also receiving dibenzodiazepine derivates (like clozapine, olanzapine). Conclusion Our data showed that schizophrenic patients treated with antipsychotics 5 years or longer had elevated blood glucose levels more frequently than the general population.

Schizophrenie - Antipsychotika - Hyperglykämie - Diabetes mellitus

schizophrenia - antipsychotics - hyperglycemia - diabetes mellitus

Literatur

• 1 Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia.  Br J Psychiatry. 2000;  177 212-217
• 2 Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality.  Br J Psychiatry. 2001;  179 498-502
• 3 Palmer B A, Pankratz V S, Bostwick J M. The lifetime risk of suicide in schizophrenia: a reexamination.  Arch Gen Psychiatry. 2005;  62 247-253
• 4 Curkendall S M, Mo J, Glasser D B, Rose Stang M, Jones J K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada.  J Clin Psychiatry. 2004;  65 715-720
• 5 Enger C, Weatherby L, Reynolds R F, Glasser D B, Walker A M. Serious cardiovascular events and mortality among patients with schizophrenia.  J Nerv Ment Dis. 2004;  192 19-27
• 6 Casey D E, Haupt D W, Newcomer J W, Henderson D C, Sernyak M J, Davidson M, Lindenmayer J P, Manoukian S V, Banerji M A, Lebovitz H E, Hennekens C H. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.  J Clin Psychiatry. 2004;  65, Suppl 7 4-18
• 7 Jin H, Meyer J M, Jeste D V. Atypical antipsychotics and glucose dysregulation: a systematic review.  Schizophr Res. 2004;  71 195-212
• 8 Wetterling T. Diabetes mellitus Typ II - induziert durch „atypische” Neuroleptika?.  Fortschr Neurol Psychiat. 2003;  71 312-322
• 9 Miller E A, Leslie D L, Rosenheck R A. Incidence of new-onset diabetes mellitus amongs patients receiving atypical neuroleptics in the treatment of mental illness.  J Nerv Ment Dis. 2005;  193 387-395
• 10 Henderson D C, Cagliero E, Gray C, Nasrallah R A, Hayden D L, Schoenfeld D A, Goff D C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.  Am J Psychiatry. 2000;  157 975-981
• 11 Farwell W R, Stump T E, Wang J. et al . Weight gain and new onset diabetes associated with olanzapine and risperidone.  J Gen Intern Med. 2004;  19 1200-1205
• 12 Barrett E J. Poster. Orlando; American Diabetes Association 2004
• 13 Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes.  Am J Med. 2001;  111 716-723
• 14 Koller E A, Doraiswamy P M. Olanzapine-associated diabetes mellitus.  Pharmacotherapy. 2002;  22 841-852
• 15 Koller E A, Cross J T, Doraiswamy P M, Schneider B S. Risperidone-associated diabetes mellitus: a pharmacovigilance study.  Pharmacotherapy. 2003;  23 735-744
• 16 Koller E A, Weber J, Doraiswamy P M, Schneider B S. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus.  J Clin Psychiatry. 2004;  65 857-863
• 17 Thefeld W. Prävalenz des Diabetes mellitus in der erwachsenen Bevölkerung Deutschlands.  Gesundheitswesen. 1999;  61, Sonderheft 2 S85-S89
• 18 Wetterling T, Schneider B, Weber B. Hyperlipidämie bei langjähriger neuroleptischer Behandlung. Psychiat Prax (im Druck)
• 19 Expert Committee on the Diagnosis and Classification of Diabetes mellitus: report of the Expert Committee on Diagnosis and Classification of diabetes mellitus.  Diabetes Care. 1997;  20 1183-1197
• 20 Dilling H, Mombour W, Schmidt M H. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F) Klinisch-diagnostische Leitlinien. 4. Aufl. Bern; Huber 2000
• 21 Bergmann K E, Mensink G B. Körpermaße und Übergewicht.  Gesundheitswesen. 1999;  61, Sonderheft 2 S115-120
• 22 Sernyak M J, Leslie D L, Alarcon R D, Losonczy M F, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.  Am J Psychiatry. 2002;  159 561-566
• 23 Koro C E, Fedder D O, L'Italien G J, Weiss S S, Magder L S, Kreyenbuhl J, Revicki D A, Buchanan R W. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.  BMJ. 2002;  325 243-245
• 24 Lindenmayer J P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy J P, Cooper T B, Chakos M, Lieberman J A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.  Am J Psychiatry. 2003;  160 290-296
• 25 Henderson D C, Cagliero E, Copeland P M, Borba C P, Evins E, Hayden D, Weber M T, Anderson E J, Allison D B, Daley T B, Schoenfeld D, Goff D C. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.  Arch Gen Psychiatry. 2005;  62 19-28
• 26 Newcomer J W, Haupt D W, Fucetola R, Melson A K, Schweiger J A, Cooper B P, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.  Arch Gen Psychiatry. 2002;  59 337-345
• 27 Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes.  Diabetes Care. 2004;  27 596-601